-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Malaria investigational vaccine
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Parasitic diseases | Malaria | Phase 2b | Matrix-M™ adjuvant |
Therapeutic area
Parasitic diseases
Infectious disease
Malaria
Status
Phase 2b
Technology
Matrix-M™ adjuvant
About the candidate
R21* is a protein-based investigational vaccine developed by the University of Oxford, using our Matrix-M™ adjuvant technology.1 This investigational vaccine is specifically designed to help protect against malaria.
Why it matters
Malaria remains a significant global burden of disease,2 infecting nearly 230 million people worldwide in 2019 alone, with an estimated 409,000 deaths. New, effective vaccines are urgently needed to address this threat.1
R21 has been evaluated in safety and efficacy trials in both adults and children.
*Investigational vaccine created and trial sponsored by University of Oxford in collaboration with Serum Institute of India, with Matrix-M adjuvant.
- Matrix-M pipeline. 2021. Data on File.
- Malaria Fact Sheet. WHO. 1 Apr 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/malaria [Accessed 3 Sept 2021].